TW200507870A - GLP-1 analog fusion proteins - Google Patents

GLP-1 analog fusion proteins

Info

Publication number
TW200507870A
TW200507870A TW093116970A TW93116970A TW200507870A TW 200507870 A TW200507870 A TW 200507870A TW 093116970 A TW093116970 A TW 093116970A TW 93116970 A TW93116970 A TW 93116970A TW 200507870 A TW200507870 A TW 200507870A
Authority
TW
Taiwan
Prior art keywords
fusion proteins
glp
inhibiting
analog fusion
intestinal
Prior art date
Application number
TW093116970A
Other languages
English (en)
Chinese (zh)
Inventor
Wolfgang Glaesner
Jr Rohn Lee Millican
Andrew Mark Vick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200507870(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TW200507870A publication Critical patent/TW200507870A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093116970A 2003-06-12 2004-06-11 GLP-1 analog fusion proteins TW200507870A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47788003P 2003-06-12 2003-06-12

Publications (1)

Publication Number Publication Date
TW200507870A true TW200507870A (en) 2005-03-01

Family

ID=33551775

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093116970A TW200507870A (en) 2003-06-12 2004-06-11 GLP-1 analog fusion proteins

Country Status (28)

Country Link
US (2) US7452966B2 (OSRAM)
EP (2) EP2368909A1 (OSRAM)
JP (1) JP4629047B2 (OSRAM)
KR (1) KR100758755B1 (OSRAM)
CN (2) CN1802386B (OSRAM)
AR (1) AR044776A1 (OSRAM)
AT (1) ATE525395T1 (OSRAM)
AU (1) AU2004251145C1 (OSRAM)
BE (1) BE2015C007I2 (OSRAM)
BR (1) BRPI0411132B8 (OSRAM)
CA (1) CA2528591C (OSRAM)
CY (2) CY1111991T1 (OSRAM)
DK (1) DK1641823T3 (OSRAM)
EA (1) EA008831B1 (OSRAM)
ES (1) ES2371072T3 (OSRAM)
FR (1) FR15C0010I2 (OSRAM)
HR (1) HRP20110714T1 (OSRAM)
HU (1) HUS1500024I1 (OSRAM)
IL (1) IL171926A (OSRAM)
LT (1) LTC1641823I2 (OSRAM)
MX (1) MXPA05013565A (OSRAM)
NZ (1) NZ543292A (OSRAM)
PL (1) PL1641823T3 (OSRAM)
PT (1) PT1641823E (OSRAM)
SI (1) SI1641823T1 (OSRAM)
TW (1) TW200507870A (OSRAM)
UA (1) UA87458C2 (OSRAM)
WO (1) WO2005000892A2 (OSRAM)

Families Citing this family (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
JP2003531590A (ja) 2000-04-12 2003-10-28 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
MXPA04003798A (es) * 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
HRP20110714T1 (hr) * 2003-06-12 2011-11-30 Eli Lilly And Company Fuzijski proteini analoga glp-1
CA2554089C (en) 2004-02-09 2013-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
PT1831252E (pt) * 2004-12-22 2009-09-17 Lilly Co Eli Formulações de proteínas de fusão de análogos de glp-1
WO2006124529A1 (en) * 2005-05-13 2006-11-23 Eli Lilly And Company Glp-1 pegylated compounds
EP1920061A4 (en) * 2005-07-27 2009-05-13 Wang Qinghua GLP / 1 / EXENDIN 4 IGG FC FUSION CONSTRUCTS FOR THE TREATMENT OF DIABETES
WO2007016764A1 (en) 2005-08-06 2007-02-15 Qinghua Wang Composition and method for prevention and treatment of type i diabetes
ES2336575T3 (es) * 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
JP2009514508A (ja) * 2005-10-24 2009-04-09 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
HRP20160866T1 (hr) * 2005-11-04 2016-10-07 Glaxosmithkline Llc Postupci primjene hipoglikemijskih sredstava
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007240313B2 (en) 2006-04-20 2012-02-02 Amgen Inc. GLP-1 compounds
WO2008028117A2 (en) * 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
JP5395664B2 (ja) * 2006-09-06 2014-01-22 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 融合ペプチド治療用組成物
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2097096B1 (en) 2006-12-22 2017-05-31 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2008205229B2 (en) * 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
JP2010518039A (ja) 2007-02-12 2010-05-27 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー カザールタイプ・セリン・プロテアーゼ阻害剤の治療への応用
EP2487184A1 (en) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5431171B2 (ja) * 2007-03-15 2014-03-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 自己免疫障害の処置
US7985731B2 (en) * 2007-06-19 2011-07-26 Otsuka Chemical Holdings Co., Ltd. Sugar chain added GLP-1 peptide
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
ES2646614T3 (es) * 2007-08-03 2017-12-14 Eli Lilly And Company Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
JP5669582B2 (ja) 2007-10-30 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト
EP2214691B1 (en) * 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN101983066B (zh) * 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AU2009260301B2 (en) * 2008-06-17 2015-09-03 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
CA2729296A1 (en) * 2008-06-17 2010-01-28 Richard D. Dimarchi Gip-based mixed agonists for treatment of metabolic disorders and obesity
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
KR101651703B1 (ko) 2008-10-10 2016-08-26 암젠 인크 Ｆｇｆ21 돌연변이체 및 이의 용도
KR20110110174A (ko) 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
MX2011011709A (es) 2009-05-05 2012-02-29 Amgen Inc Mutantes fgf21 y usos de los mismos.
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
CN102459325B (zh) 2009-06-16 2015-03-25 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
EP2443145A1 (en) * 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
WO2011043530A1 (ko) * 2009-10-09 2011-04-14 (주)알테오젠 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
CA2782814A1 (en) * 2009-12-02 2011-06-09 Amgen Inc. Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
MX2012011986A (es) 2010-04-15 2013-03-05 Amgen Inc RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
EP2565202A4 (en) 2010-04-30 2013-10-30 Sanwa Kagaku Kenkyusho Co PEPTIDE FOR IMPROVING THE IN VIVO STABILITY OF A PHYSIOLOGICALLY ACTIVE SUBSTANCE OR ANALOGUES AND PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ANALOGUES HAVING IN VIVO STABILITY IMPROVEMENT
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CN103079587B (zh) 2010-05-13 2016-05-11 印第安纳大学研究及科技有限公司 呈现核激素受体活性的胰高血糖素超家族肽
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
RU2580317C2 (ru) 2010-06-24 2016-04-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
JP6086067B2 (ja) 2010-12-22 2017-03-01 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Ｇｉｐレセプター活性を示すグルカゴンアナローグ
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
DK2683397T3 (en) 2011-03-09 2017-09-18 Csl Behring Gmbh FACTOR XII INHIBITORS FOR ADMINISTRATION OF MEDICAL PROCEDURES COMPREHENSIVE CONTACT WITH ARTIFICIAL SURFACES
MX354359B (es) 2011-03-29 2018-02-28 Roche Glycart Ag Variantes de fragmento cristalizable (fc) de los anticuerpos.
WO2012177444A2 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR101972617B1 (ko) 2011-06-22 2019-04-25 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-항진제들
RU2660370C2 (ru) 2011-07-22 2018-07-05 Цсл Беринг Гмбх Ингибирующие моноклональные антитела против фактора xii/xiia и их применения
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
EP2872534B1 (en) 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
MY170126A (en) * 2012-09-12 2019-07-05 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014084508A1 (ko) 2012-11-27 2014-06-05 (주)알테오젠 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물
TWI711632B (zh) 2012-11-27 2020-12-01 美商拜奧馬林製藥公司 靶向治療性溶小體酶融合蛋白及其用途
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
SG10201809779RA (en) 2013-03-11 2018-12-28 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
AU2014241743B2 (en) 2013-03-14 2018-07-05 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CA2916399C (en) 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
CN104592381A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种利拉鲁肽中间体多肽的制备方法
EP3125921B1 (en) 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
CN106471010A (zh) 2014-03-19 2017-03-01 建新公司 靶向模块的位点特异性糖工程化
EA201691795A1 (ru) * 2014-03-31 2017-03-31 Ханми Фарм. Ко., Лтд. Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
PL3157548T3 (pl) 2014-06-18 2022-01-17 Csl Behring Gmbh Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
CA2953593C (en) 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
DK3172227T3 (da) 2014-07-21 2019-12-02 Delinia Inc Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme
KR20170035910A (ko) 2014-08-11 2017-03-31 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
CN104293834B (zh) * 2014-10-11 2018-03-23 上海兴迪金生物技术有限公司 GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
HRP20191292T1 (hr) 2014-12-23 2019-10-18 Novo Nordisk A/S Derivati fgf21 i njihova upotreba
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
SG11201708754XA (en) 2015-05-22 2017-12-28 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
RU2017145014A (ru) 2015-05-22 2019-06-24 Цсл Беринг Ленгнау Аг Усеченные полипептиды фактора фон виллебранда для лечения гемофилии
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
KR102668200B1 (ko) 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
BR112018013861A2 (pt) 2016-01-07 2018-12-18 Csl Behring Recombinant Facility Ag polipeptídeo, complexo, composição farmacêutica, métodos para tratar um distúrbio de coagulação sanguínea, para produzir um polipeptídeo e um dímero de um polipeptídeo, para aumentar a meia vida do fator viii e para aumentar a dimerização do dito polipeptídeo, uso de um polipeptídeo, kit farmacêutico, plasmídeo ou vetor, e, célula hospedeira
CA3008448A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3440107A4 (en) 2016-04-06 2020-02-19 CSL Limited METHOD FOR TREATING ATHEROSCLEROSIS
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
BR112019009581A2 (pt) 2016-11-10 2019-10-08 Yuhan Corp composição farmacêutica para evitar ou tratar hepatite, fibrose hepática, e cirrose hepática que compreende proteínas de fusão
CN109922824A (zh) 2016-11-11 2019-06-21 康诺贝林伦瑙有限公司 用于治疗血友病的截短的冯维勒布兰德因子多肽
US11890327B2 (en) 2016-11-11 2024-02-06 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
EP3351262A1 (en) 2016-12-30 2018-07-25 Istanbul Universitesi Rektorlugu Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
US12145974B2 (en) 2017-03-14 2024-11-19 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin
EA201992516A1 (ru) 2017-04-21 2020-04-09 Юхан Корпорейшн Способ получения бифункциональных белков и их производных
HUE063776T2 (hu) 2017-06-01 2024-01-28 Lilly Co Eli Dulaglutid krónikus vesebetegség kezelésére
BR112019024410A2 (pt) 2017-06-20 2020-07-14 Amgen Inc. método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
EP4353250A3 (en) 2017-06-21 2024-06-19 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
ES2966835T3 (es) 2017-06-22 2024-04-24 CSL Behring Lengnau AG Modulación de la inmunogenicidad del FVIII por VWF truncado
CA3071337A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
IL304574B2 (en) 2017-09-22 2025-08-01 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof
CN120478602A (zh) 2017-11-21 2025-08-15 伊莱利利公司 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物
US11752173B2 (en) 2017-12-19 2023-09-12 Beijing Jiyuan Biological Technology Co., Ltd. FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
US11491235B2 (en) 2017-12-22 2022-11-08 Kb Biomed Inc. Oral gene carrier and use thereof
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CN110128525B (zh) 2018-02-08 2022-08-26 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
KR20200135618A (ko) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
AU2019308089B2 (en) 2018-07-19 2025-04-10 D&D Pharmatech Inc. Pharmaceutical composition comprising polypeptide
CN110878127B (zh) 2018-09-06 2022-06-28 浙江柏拉阿图医药科技有限公司 长效重组GLP1-Fc-CD47蛋白及其制备和用途
PE20211078A1 (es) 2018-10-22 2021-06-09 Janssen Pharmaceutica Nv Proteinas de fusion de peptido similar al glucagon 1 (glp1)-factor de diferenciacion de crecimiento 15 (gdf15) y usos de estas
CN111234000B (zh) * 2018-11-28 2023-05-26 鲁南制药集团股份有限公司 艾塞纳肽类似物
CN111269312B (zh) * 2018-12-04 2023-05-09 鲁南制药集团股份有限公司 一种异源融合蛋白质
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
EP3935075A4 (en) * 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. POLYPEPTIDIC MOLECULE AND ITS APPLICATION
MX2021010737A (es) 2019-03-08 2021-09-28 Amgen Inc Terapia de combinacion por factor de diferenciacion del crecimiento 15.
JP7728176B2 (ja) 2019-03-15 2025-08-22 イーライ リリー アンド カンパニー 保存製剤
MA55529A (fr) 2019-04-03 2022-02-09 Genzyme Corp Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
SG11202111570TA (en) * 2019-04-23 2021-11-29 Lg Chemical Ltd Fusion polypeptide comprising fc region of immunoglobulin and gdf15
SG11202112117TA (en) 2019-05-17 2021-12-30 Univ Zuerich Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023543125A (ja) 2020-08-24 2023-10-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｇｌｐ－１受容体アゴニスト融合物をコードするウイルスベクター及び代謝性疾患の治療におけるその使用
CN114106194B (zh) * 2020-08-31 2024-01-16 中国科学院天津工业生物技术研究所 一种用于治疗糖尿病和/或肥胖症的融合蛋白
JP2023551193A (ja) 2020-11-20 2023-12-07 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 抗体関連型拒絶反応を処置するための方法
CN114685644A (zh) 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
US20250339492A1 (en) 2021-02-01 2025-11-06 Csl Behring Ag Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
JP2024517857A (ja) 2021-05-07 2024-04-23 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 組換えハプトグロビン（Ｈｐ）ベータ鎖を作製するための発現系
JP2024524530A (ja) 2021-07-06 2024-07-05 スジョウ・アルファマブ・カンパニー・リミテッド 融合タンパク質及びその使用
CA3224743A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
AR129357A1 (es) 2022-05-18 2024-08-14 Protomer Tech Inc Compuestos aromáticos que contienen boro y análogos de insulina relacionados
CN114774496B (zh) * 2022-06-21 2022-10-04 北京惠之衡生物科技有限公司 一种高密度发酵制备glp-1类似物的方法
KR20250058762A (ko) 2022-09-02 2025-04-30 체에스엘 베링 아게 과도한 발기 반응 또는 발기 부전을 치료하거나 예방하는 데 사용하기 위한 합토글로빈
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024132147A1 (en) 2022-12-22 2024-06-27 Lifearc Galanin-2 receptor agonists
WO2024197132A1 (en) 2023-03-23 2024-09-26 Eli Lilly And Company Methods of producing fc-containing proteins
WO2025069009A1 (en) 2023-09-29 2025-04-03 Graviton Bioscience Bv Rock2 inhibitors in the treatment of obesity
WO2025122835A2 (en) 2023-12-08 2025-06-12 Eli Lilly And Company Methods of producing fc-containing proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
ES2279508T3 (es) 1992-11-13 2007-08-16 Immunex Corporation Ligando elk, una citoquina.
NZ292124A (en) * 1994-07-29 1998-10-28 Smithkline Beecham Plc Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6190909B1 (en) 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6376653B1 (en) 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
EP1180121B9 (en) 1999-05-17 2004-09-08 Conjuchem, Inc. Long lasting insulinotropic peptides
IL153453A0 (en) 2000-06-16 2003-07-06 Lilly Co Eli Glucagon-like peptide-1 analogs
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
HRP20110714T1 (hr) * 2003-06-12 2011-11-30 Eli Lilly And Company Fuzijski proteini analoga glp-1

Also Published As

Publication number Publication date
CN1802386A (zh) 2006-07-12
BRPI0411132B1 (pt) 2016-12-13
EP1641823A2 (en) 2006-04-05
CY2015002I2 (el) 2017-04-05
WO2005000892A3 (en) 2005-03-03
CN101974090B (zh) 2015-06-17
HK1149566A1 (en) 2011-10-07
FR15C0010I2 (fr) 2015-07-24
SI1641823T1 (sl) 2011-12-30
US8273854B2 (en) 2012-09-25
KR20060022262A (ko) 2006-03-09
HUS1500024I1 (hu) 2017-04-28
AR044776A1 (es) 2005-10-05
KR100758755B1 (ko) 2007-09-14
LTC1641823I2 (lt) 2016-12-12
US20070036806A1 (en) 2007-02-15
US20090074769A1 (en) 2009-03-19
UA87458C2 (ru) 2009-07-27
EP2368909A1 (en) 2011-09-28
AU2004251145B2 (en) 2010-09-09
JP2007536902A (ja) 2007-12-20
BE2015C007I2 (OSRAM) 2023-08-09
BRPI0411132A (pt) 2006-07-18
CN101974090A (zh) 2011-02-16
IL171926A0 (en) 2006-04-10
ES2371072T3 (es) 2011-12-27
MXPA05013565A (es) 2006-03-09
CY2015002I1 (el) 2015-11-04
WO2005000892A2 (en) 2005-01-06
NZ543292A (en) 2008-04-30
EP1641823B1 (en) 2011-09-21
PL1641823T3 (pl) 2012-02-29
BRPI0411132B8 (pt) 2021-05-25
CY1111991T1 (el) 2015-11-04
US7452966B2 (en) 2008-11-18
DK1641823T3 (da) 2011-12-12
PT1641823E (pt) 2011-11-08
ATE525395T1 (de) 2011-10-15
CN1802386B (zh) 2010-12-15
HRP20110714T1 (hr) 2011-11-30
AU2004251145C1 (en) 2011-04-14
EA200600015A1 (ru) 2006-06-30
FR15C0010I1 (OSRAM) 2015-03-13
AU2004251145A1 (en) 2005-01-06
CA2528591C (en) 2013-01-08
JP4629047B2 (ja) 2011-02-09
CA2528591A1 (en) 2005-01-06
EA008831B1 (ru) 2007-08-31
LTPA2015007I1 (lt) 2015-03-25
IL171926A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
TW200507870A (en) GLP-1 analog fusion proteins
IL183285A0 (en) Glp-1 analog fusion protein formulations
UA92451C2 (en) Polyethelene glycol link glp-1 compounds
NO20076415L (no) GLP-1 pegylerte forbindelser
SG130189A1 (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2008155900A1 (ja) 糖鎖付加glp-1ペプチド
MX2009002999A (es) Analogos de insulina resistentes a proteasa.
CY1116917T1 (el) Αναλογα οξυντομοντουλινης
PL1670828T3 (pl) W pełni ludzkie przeciwciała przeciwko ludzkiemu 4-1BB (CD137)
DE60012721D1 (de) Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
WO2005059155A3 (de) Verfahren zur isolierung von methionin aus einem fermentationsüberstand
WO2006042152A3 (en) Vasoactive intestinal polypeptide pharmaceuticals
TNSN05065A1 (en) Use of prebiotics for the treatment and prevention of hyperglycaemic syndromes
WO2007059262A3 (en) Process for improving water holding capacity and tenderness in cooked protein food products
WO2009069738A1 (ja) 風味改良剤
RU2005120893A (ru) Способ повышения продуктивности цыплят-бройлеров
ITSV20020049A1 (it) Procedimento di tostatura per pasta alimentare.
TW200603829A (en) A mixture of food allergens and a method for detecting the food allergens and allergy-inducing foods